|
|||||
|
|
Current and future therapeutic approaches for the treatment of small cell lung cancer |
|
| Authors: | Antonio Rossi Rebecca Tay Jaseela Chiramel Arsela Prelaj Raffaele Califano |
| Affiliation: | 1. Division of Medical Oncology, Scientific Institute for Research and Health Care (IRCCS) “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Italy;2. Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK;3. Department of Radiological, Pathological and Oncological Science, Sapienza University of Rome, Italy;4. Department of Medical Oncology, Manchester University NHS Foundation Trust, Manchester, UK;5. Division of Cancer Sciences, University of Manchester, Manchester, UK |
| Abstract: | Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1 year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC. Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC. Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC. |
| Keywords: | Durvalumab immunotherapy ipilimumab nivolumab pembrolizumab rovalpituzumab tesirine SCLC second-line targeted therapy tremelimumab |